Pharmaceuticals News and Research

RSS

Bioniche granted additional patent for mycobacterial cell wall technology

Bioniche Life Sciences Inc., a research-based, technology-driven human and animal health biopharmaceutical company, today announced that it has had a new patent issued by the United States Patent and Trademark Office (USPTO) on its core mycobacterial cell wall technology.

18 May 2005

Big pharma gets the desired results from medical journals

“Medical journals are an extension of the marketing arm of pharmaceutical companies,” argues Richard Smith, former editor of the BMJ and now Chief Executive of UnitedHealth Europe, in a provocative essay published in the open access international health journal PLoS Medicine.

17 May 2005

Antibody combined with cancer drug shows promise against breast tumors

An antibody that targets the blood vessels nourishing tumors significantly reduced breast cancer formation and growth in mice when combined with a current cancer drug, according to researchers at UT Southwestern Medical Center.

16 May 2005

More health benefits from green tea

Green tea appears to protect against cancer by affecting a "promiscuous" protein that pharmaceutical experts are already targeting in an effort to develop a new drug to stop the disease, scientists at the University of Rochester Medical Center have found.

16 May 2005

Tarvacin equivalent plus Docetaxel inhibits breast tumor growth by 93%

Peregrine Pharmaceuticals, Inc., today announced that a research article titled "A Monoclonal Antibody that Binds Anionic Phospholipids on Tumor Blood Vessels Enhances the Antitumor Effect of Docetaxel on Human Breast Tumors in Mice" was published in the May 15 issue of Cancer Research.

16 May 2005

Zometa reduces bone loss in patients receiving breast cancer treatment

Data presented at the American Society of Clinical Oncology (ASCO) annual meeting in Orlando, Florida, demonstrate that Zometa (zoledronic acid), an intravenous bisphosphonate, was shown to inhibit bone loss in postmenopausal women treated with Femara (letrozole) in the adjuvant breast cancer setting (directly following surgery to prevent cancer recurrence).

16 May 2005

Molecule found in liver cells could explain a lot about the relationship between diet, lipid levels in blood, and atherosclerosis

A team of researchers at the University of Pennsylvania School of Medicine have made a discovery that a molecule found in liver cells is important in explaining the relationship between diet, lipid levels in blood, and atherosclerosis.

15 May 2005

New drug which quickly dissolves blood clots and returns circulation to normal

Cardiovascular patients now have a greater chance of surviving heart attacks after Chinese scientists developed a new drug which quickly dissolves blood clots and returns circulation to normal.

15 May 2005

Rearing sea sponges that contain substances of interest to the pharmaceutical industry

Dutch researcher Nicole de Voogd has investigated the possibilities for rearing sea sponges in Indonesia. Some of these sponges contain substances of interest to the pharmaceutical industry. As these are increasingly difficult to obtain, there is growing interest in alternative methods of exploitation, such as rearing sponges.

15 May 2005

Researchers to explore genome of disease-fighting fungus

A team of Texas Agricultural Experiment Station scientists will soon begin genome sequencing a disease-fighting fungus used to protect crops, which has implications for both agriculture and the pharmaceutical industry.

15 May 2005

New anticancer drug SU11248 shows continued response for patients with late-stage kidney cancer

Recent studies of a new anticancer drug show continued response for patients with late-stage kidney cancer. Robert Motzer, MD, attending physician at Memorial Sloan-Kettering Cancer Center (MSKCC), reported a response rate of 40 percent in patients with metastatic (advanced) renal cell (kidney) cancer who received SU11248 in second-line therapy.

15 May 2005

First advance in pancreatic cancer treatment in a decade offers new hope

The first advance in pancreatic cancer treatment in a decade has been achieved by researchers in a Canadian-led study, and at last gives some encouragement to scientists and invigorates a field that has experienced more than its share of disheartening failures.

15 May 2005

Fat-fighting drugs may be a far riskier business than they seem

Experts are warning that despite the fact that obesity is one of the biggest preventable causes of death, fat-fighting drugs may be a far riskier business than they seem, particularly for investors.

11 May 2005

NIAID has awarded 10 grants and 2 contracts totaling approximately $27 million to fund development of new therapeutics and vaccines against bioterrorism

The National Institute of Allergy and Infectious Diseases (NIAID) has awarded 10 grants and 2 contracts totaling approximately $27 million to fund development of new therapeutics and vaccines against some of the most deadly agents of bioterrorism including anthrax, botulinum toxin, Ebola virus, pneumonic plague, smallpox and tularemia.

11 May 2005

Canada may ban bulk exports of drugs to the United States

In a move to forestall a potential drug shortage in Canada, Canadian Health Minister Ujjal Dosanjh, is contemplating imposing a ban on bulk exports of drugs to the United States.

10 May 2005

Vaccine against Alzheimer's disease may still be on the cards

A new, but modified, trial of an Alzheimer's vaccine has begun in the U.S. despite an earlier one being abandoned in 2002 due to safety concerns.

10 May 2005

Pharmacies in supermarkets: Where's the public benefit?

Protecting public health is more important than Woolworths' profits and should be the primary consideration in any government decision over whether to allow pharmacies in supermarkets, Pharmaceutical Society of Australia Vice-President Frank Payne said yesterday.

10 May 2005

Combining behavior modification therapy with medication is the most effective way to improve the behavior of many ADHD children

In fact, when the two are combined, the study showed, the amount of medication required to achieve the same results as use of medication alone can be reduced by two-thirds.

10 May 2005

Expert analyzes why manufacturers have gradually abandoned vaccines

Recent shortages of vaccines, most recently the flu vaccine during the past winter, are not short-term glitches--they reflect long-term problems in the vaccine industry. A variety of social, legal and economic forces have caused pharmaceutical companies to withdraw their commitment to vaccines, according to pediatrician and vaccine expert Paul A. Offit, M.D., chief of Infectious Diseases at The Children's Hospital of Philadelphia.

10 May 2005